Author:
Chin N X,Neu N M,Labthavikul P,Saha G,Neu H C
Abstract
A-56268 was compared with erythromycin, roxithromycin (RU 28965), and perorally administered antimicrobial agents. Its in vitro activity was similar to that of erythromycin and slightly greater than that of roxithromycin, with beta-hemolytic streptococci and Streptococcus pneumoniae inhibited by less than 2 micrograms of A-56268 per ml (50% inhibited by 0.06 microgram/ml). Streptococcus pyogenes, S. agalactiae, S. Pneumoniae, and S. faecalis resistant to erythromycin were resistant to A-56268, and 4 micrograms/ml inhibited 90% of Haemophilus influenzae isolates.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference4 articles.
1. In vitro comparison of the activity of RU 29865, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria;BarIam T.;Antimicrob. Agents Chemother.,1984
2. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs;Jones R. N.;Antimicrob. Agents Chemother.,1983
3. Effect of several components of anaerobic incubation on antibiotic susceptibility test results;Rosenblatt J. E.;Antimicrob. Agents Chemother.,1972
4. Erythromycin: a microbiological and clinical perspective after 30 years of clinical use;Washington J. A.;Mayo Clin. Proc.,1985
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献